298 related articles for article (PubMed ID: 26497699)
21. Diagnostic value of [
Jamsek J; Hocevar M; Bergant D; Zaletel K; Rep S; Lezaic L
Ann Nucl Med; 2021 Apr; 35(4):429-437. PubMed ID: 33544320
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
23. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.
Treglia G; Cocciolillo F; Di Nardo F; Poscia A; de Waure C; Giordano A; Rufini V
Acad Radiol; 2012 Oct; 19(10):1290-9. PubMed ID: 22819076
[TBL] [Abstract][Full Text] [Related]
24. 18F-DOPA PET/CT in Orbital Metastasis From Medullary Thyroid Carcinoma.
Ruiz JB; Orré M; Cazeau AL; Henriques de Figueiredo B; Godbert Y
Clin Nucl Med; 2016 Jun; 41(6):e296-7. PubMed ID: 27055131
[TBL] [Abstract][Full Text] [Related]
25. Parathyroid Glands Hyperplasias Mimicking Medullary Thyroid Carcinoma Metastatic Lymph Nodes on 18F-DOPA PET/CT.
Terroir M; Grimaldi S; Hartl D; Leboulleux S; Deandreis D
Clin Nucl Med; 2019 Aug; 44(8):e497-e498. PubMed ID: 31274634
[TBL] [Abstract][Full Text] [Related]
26. The role of
Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
[TBL] [Abstract][Full Text] [Related]
27. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
29. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
30. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
31. Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?: Results From a Dynamic Acquisition Study.
Taralli S; Lorusso M; Capotosti A; Lanni V; Indovina L; Rufini V
Clin Nucl Med; 2020 Mar; 45(3):e134-e140. PubMed ID: 31977485
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis.
Lee SW; Shim SR; Jeong SY; Kim SJ
Clin Nucl Med; 2020 May; 45(5):341-348. PubMed ID: 32049723
[TBL] [Abstract][Full Text] [Related]
34. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
[TBL] [Abstract][Full Text] [Related]
35. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Beheshti M; Pöcher S; Vali R; Waldenberger P; Broinger G; Nader M; Kohlfürst S; Pirich C; Dralle H; Langsteger W
Eur Radiol; 2009 Jun; 19(6):1425-34. PubMed ID: 19156423
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
37. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
39.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
40. The Role of
Araz M; Soydal Ç; Demir Ö; Gökcan MK; Küçük NÖ
Mol Imaging Radionucl Ther; 2023 Feb; 32(1):1-7. PubMed ID: 36815513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
